Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.22 per share a year ago.
Quest Diagnostics beats quarterly results estimates on diagnostic test demand
Laboratory operator Quest Diagnostics beat Wall Street estimates for third-quarter profit and revenue on Tuesday, helped by robust demand for its diagnostic tests.
Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Quest Diagnostics (DGX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging populations and preventive medical testing, promising 10% annual returns and 6-8% annual dividend growth. DGX's financials have stabilized post-Covid, with revenue, earnings, and free cash flow rising, supported by share buybacks and strategic acquisitions.
DGX Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
Quest Diagnostics is expected to deliver robust base business growth in the third quarter of 2024.
Should You Add Quest Diagnostics Stock to Your Portfolio Right Now?
DGX's strength in Advanced Diagnostics and robust base business volumes are encouraging.
Is Quest Diagnostics (DGX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Quest Diagnostics Stock Gains From New Offerings, Customer Wins
A key driver in Brain Health growth is Quest Diagnostics' Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF tests.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DGX Stock to Benefit From New Partnership With Sentara Health Plans
Quest Diagnostics extends services in Virginia and Florida via a partnership with Sentara Health Plans.
DGX Stock Likely to Gain From Allina Health's Select Lab Assets Buyout
With the completion of the acquisition, Allina Health's clinic physicians will now have access to Quest Diagnostics' laboratory services.
